Alliance for Clinical Trials in Oncology

Alliance for Clinical Trials in Oncology logo
🇺🇸United States
Ownership
Private
Established
2011-01-01
Employees
251
Market Cap
-
Website
https://www.allianceforclinicaltrialsinoncology.org
tradingview.com
·

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx

Cabometyx® (cabozantinib) showed significant reduction in disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, according to data from the CABINET Phase III trial. The results were presented at ESMO 2024 and published in the New England Journal of Medicine. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency.
ipsen.com
·

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in ...

Cabometyx (cabozantinib) showed significant reduction in disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, according to final data from the CABINET Phase III trial. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency. The data were presented at ESMO 2024 and published in the New England Journal of Medicine.
globenewswire.com
·

Final results from CABINET Phase III trial reinforce

Final CABINET Phase III trial data showed Cabometyx significantly reduced disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, presented at ESMO 2024 and published in NEJM. Ipsen has submitted an extension of indication Marketing Authorization to the EMA, addressing limited treatment options for advanced NETs.
© Copyright 2024. All Rights Reserved by MedPath